» Articles » PMID: 31602184

The Impact of Sacral Neuromodulation on Sexual Dysfunction

Overview
Journal Curr Urol
Specialty Urology
Date 2019 Oct 12
PMID 31602184
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Sacral neuromodulation (SNM) is a well-established treatment in several urinary and bowel dysfunctions, nevertheless its role on sexual dysfunction remains unclear. We evaluate the impact of SNM on sexual function and its association with age at SNM, functional diagnosis and post-void residual urine (PVR) before SNM.

Methods: Patients who had SNM were retrospectively analyzed. Sexual function was assessed before and after treatment with the International Index of Erectile Function (IIEF-5) for men and the Female Sexual Function Index (FSFI) for women. IIEF-5 and FSFI were also associated with age at SNM, functional diagnosis, and PVR.

Results: Fifteen females and 9 males, with a median age of 41 years (26-72 years), median follow-up 20.7 months (2-53 months) were enrolled. IIEF-5 improved in 4 patients (p = 0.06), and FSFI total score in 5 (p = 0.2). There was significant association between functional diagnosis and FSFI total score (p = 0.05), and FSFI specific domains of arousal (p = 0.03), lubrication (p = 0.04), and satisfaction (p = 0.03), with significant improvement showed in patients with detrusor overactivity with impaired contractility.

Conclusion: Although gains observed in IIEF-5 and FSFI were modest, our preliminary results show that SNM may have favorable impact on sexual function.

Citing Articles

Long-term outcomes of sacral neuromodulation for low anterior resection syndrome after rectal cancer surgery.

de Miguel Valencia M, Marin G, Acevedo A, Hernando A, Alvarez A, Oteiza F Ann Coloproctol. 2024; 40(3):234-244.

PMID: 38946094 PMC: 11362764. DOI: 10.3393/ac.2023.00542.0077.


Therapeutic Approaches for Urologic Chronic Pelvic Pain Syndrome; Management: Research Advances, Experimental Targets, and Future Directions.

Ashraf S, Clarkson T, Malykhina A J Pharmacol Exp Ther. 2024; 390(2):222-232.

PMID: 38565309 PMC: 11264256. DOI: 10.1124/jpet.123.002081.


[Functional-neurosurgical treatment options for functional pelvic floor disorders : Value of sacral neuromodulation].

Maciaczyk J, Bara G, Kurth F Radiologie (Heidelb). 2023; 63(11):835-843.

PMID: 37823893 DOI: 10.1007/s00117-023-01214-8.


Sacral neuromodulation for low anterior resection syndrome: current status-a systematic review and meta-analysis.

Pires M, Severo M, Lopes A, Neves S, Matzel K, Povo A Int J Colorectal Dis. 2023; 38(1):189.

PMID: 37428256 DOI: 10.1007/s00384-023-04485-8.


Is Sacral Neuromodulation a Treatment Option for Primary Bladder Neck Obstruction?.

Alzahrani I, El-Tholoth H, Alsulihem A Cureus. 2023; 14(12):e32931.

PMID: 36699762 PMC: 9873199. DOI: 10.7759/cureus.32931.


References
1.
Lombardi G, Mondaini N, Macchiarella A, Cilotti A, Del Popolo G . Clinical female sexual outcome after sacral neuromodulation implant for lower urinary tract symptom (LUTS). J Sex Med. 2008; 5(6):1411-7. DOI: 10.1111/j.1743-6109.2008.00812.x. View

2.
Jones J, Van de Putte D, Ridder D, Knowles C, OConnell R, Nelson D . A Joint Mechanism of Action for Sacral Neuromodulation for Bladder and Bowel Dysfunction?. Urology. 2016; 97:13-19. DOI: 10.1016/j.urology.2016.05.032. View

3.
Yang C, Jiang X . Clinical autonomic neurophysiology and the male sexual response: an overview. J Sex Med. 2009; 6 Suppl 3:221-8. PMC: 2712633. DOI: 10.1111/j.1743-6109.2008.01180.x. View

4.
Hassouna M, Sadri H . Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective. Can Urol Assoc J. 2015; 9(7-8):242-7. PMC: 4537333. DOI: 10.5489/cuaj.2711. View

5.
Peters K, Killinger K, Gilleran J, Bartley J, Wolfert C, Boura J . Predictors of reoperation after sacral neuromodulation: A single institution evaluation of over 400 patients. Neurourol Urodyn. 2015; 36(2):354-359. DOI: 10.1002/nau.22929. View